In a randomized, double-blind, placebo-controlled trial
published in the NEJM
, involving 1884 patients with atrial fibrillation, who had warfarin treatment
interrupted for an elective operation or invasive procedure, forgoing bridging anticoagulation was non-inferior to perioperative
bridging with low-molecular-weight heparin for the prevention of arterial thromboembolism (stroke, systemic embolism, or transient
ischemic attack) and decreased the risk of major bleeding.